Retinopathy of Prematurity—Targeting Hypoxic and Redox Signaling Pathways
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThe study under review meticulously examines various publications addressing the pathogenesis and therapeutic approaches for retinopathy of prematurity, addressing the significant challenges associated with this medical condition. The paper is thoughtfully organized, utilizing tables and figures effectively to enhance data comprehension. The conclusions drawn are clear, well-supported by the results, and presented in high-quality scientific English.
A minor comment from this reviewer notes a slight overemphasis on self-citation in the bibliography.
Nevertheless, overall, this well-written manuscript is poised to make a substantial impact on the readers of this journal and can serve as a valuable resource in the field of research on retinopathy of prematurity.
Author Response
We appreciate the reviewer's positive comments. However, we would like to address one concern related to the perceived overemphasis on self-citations in the bibliography. It is important to note that while we referenced only 10 of our own publications on ROP or oxidative stress in the retina, our collaborative efforts have contributed to over 100 studies on these topics. We believe this level of self-citation is appropriate, especially considering the manuscript includes a total of 221 citations.
Reviewer 2 Report
Comments and Suggestions for AuthorsSee attached file
Comments for author File: Comments.docx
Author Response
We greatly appreciate the reviewer for providing such positive feedback.
Reviewer 3 Report
Comments and Suggestions for AuthorsI would congratulate the authors to an excellent overview regarding the main goal : Author: This review article aims to present the pathophysiological mechanisms of ROP, including its treatment.
This review give an proper and a scientific basis for current knowledge in this field ( Classification, Diagnosis; Screening and Diagnostic Tools; Natural Course, Long-Term Sequelae, and Prognosis: Insights into the Pathophysiology of Retinopathy of Prematurity; Treatment Intervention in Retinopathy of Prematurity) I am sorry to say that in my opinion this manuscript missing more detail information about recent development in the field of Inflammatory and steroids in ROP regarding to pathophysiology and treatment. Below some recent publications.
1.A Prospective Analysis of the Retinopathy of Prematurity Correlated with the Inflammatory Status of the Extremely Premature and Very Premature Neonates. Borțea CI, Enatescu I, Dima M, Pantea M, Iacob ER, Dumitru C, Popescu A, Stoica F, Heredea RE, Iacob D. Diagnostics (Basel). 2023 Jun 18;13(12):2105.
2.Impact of postnatal steroids on peripheral avascular retina and severity of retinopathy of prematurity. Shekhawat PS, Ali MAM, Kannekanti N, Koechley H, Mhanna C, Pinto M, Farghaly MAA, Mhanna M, Aly HZ, Sears JE. Pediatr Res. 2023 Dec;94(6):1966-1972. doi: 10.1038/s41390-023-02673-4. Epub 2023 Jun 8
3.Dexamethasone Eye Drops for the Treatment of Retinopathy of Prematurity. Öhnell HM, Andreasson S, Gränse L. Ophthalmol Retina. 2022 Feb;6(2):181-182.
|
|
4. Exudative Retinal Detachment Following Laser Photocoagulation for Retinopathy of Prematurity: A Rare Complication. Moinuddin O, Bonaffini S, Besirli CG. Ophthalmic Surg Lasers Imaging Retina. 2019 Apr 1;50(4):242-246
As you know there have been some review with or without metanalysis in this field in recent years and tuhs review is important, but as inflammatory factors seems be a new and important tool in evaluation and in treatment of these children (recently even at AAO 2023), my suggestion would be that this chapter should be further described in this review.
Author Response
We sincerely appreciate the reviewer for providing these insightful comments and suggestions. Following these recommendations, we have incorporated additional content referencing the corresponding articles in the following sections:
-
Chapter 2: Diagnostic, Subheader 2.2. (lines 168–180, added sentences are underlined).
-
Chapter 3: Pathophysiology, Subheader 3.2.1. (lines 355–373, added sentences are underlined).
-
Chapter 4: Treatment, Subheaders 4.1. and 4.2.5. (lines 435–438 and 580–602, added sentences are underlined).
Round 2
Reviewer 3 Report
Comments and Suggestions for AuthorsFrom my point of view, it´s an important review